It's time to reimagine reimbursement for CAR T-cell therapy

Key Points

• To highlight and address key reimbursement challenges for CAR T-cell therapy in the US and EU healthcare systems.
• Analysis of reimbursement structures for CAR T-cell therapy in the US and EU
• Discussion of regulatory and policy landscapes
• Collaboration with the CAR T Vision Steering Committee to propose solutions
• Identification of major reimbursement issues impacting CAR T-cell therapy access
• Proposed solutions aimed at improving cost-effectiveness and patient access
• Recommendations for policy adjustments to support CAR T therapy reimbursement